What is Aura Biosciences, Inc.'s earnings per share (EPS)?

Aura Biosciences, Inc. (AURA) reported diluted earnings per share of $-1.76 for fiscal year 2025. This represents a -0.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Aura Biosciences, Inc. Financials

AURA

Source SEC Filings (10-K/10-Q) Updated Mar 30, 2026 Currency USD FYE March

This page shows Aura Biosciences, Inc. (AURA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Aura Biosciences, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.80x

For every $1 of reported earnings, Aura Biosciences, Inc. generates $0.80 in operating cash flow (-$84.7M OCF vs -$106.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$111.7M

YoY-17.7%

Aura Biosciences, Inc.'s EBITDA was -$111.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 17.7% from the prior year.

Net Income

-$106.2M

YoY-22.2%

Aura Biosciences, Inc. reported -$106.2M in net income in fiscal year 2025. This represents a decrease of 22.2% from the prior year.

EPS (Diluted)

$-1.76

YoY-0.6%

Aura Biosciences, Inc. earned $-1.76 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 0.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$85.2M

YoY-5.1%

Aura Biosciences, Inc. generated -$85.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 5.1% from the prior year.

Cash & Debt

$59.5M

YoY+87.8%

5Y CAGR+27.9%

Aura Biosciences, Inc. held $59.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

64M

YoY+28.3%

Aura Biosciences, Inc. had 64M shares outstanding in fiscal year 2025. This represents an increase of 28.3% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-77.6%

YoY-20.4pp

Aura Biosciences, Inc.'s ROE was -77.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 20.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$90.3M

YoY+23.2%

5Y CAGR+38.0%

Aura Biosciences, Inc. invested $90.3M in research and development in fiscal year 2025. This represents an increase of 23.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$447K

YoY-64.3%

5Y CAGR-10.3%

Aura Biosciences, Inc. invested $447K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 64.3% from the prior year.

AURA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$90.3M+23.2%	$73.3M+12.4%	$65.2M+54.4%	$42.2M+67.9%	$25.2M+39.5%	$18.0M
SG&A Expenses	$22.5M-1.4%	$22.8M+15.5%	$19.8M+9.4%	$18.1M+79.0%	$10.1M+142.3%	$4.2M
Operating Income	-$112.8M-17.3%	-$96.1M-13.1%	-$85.0M-41.0%	-$60.3M-71.0%	-$35.3M-58.7%	-$22.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$108K-3.6%	$112K-18.2%	$137K	$0	$0	$0
Net Income	-$106.2M-22.2%	-$86.9M-13.8%	-$76.4M-30.0%	-$58.8M-66.7%	-$35.3M-58.7%	-$22.2M
EPS (Diluted)	$-1.76-0.6%	$-1.75+9.3%	$-1.93+1.5%	$-1.96+78.1%	$-8.95	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$22.2M-3.1%	$22.9M-2.0%	$23.3M	N/A	$17.0M+0.9%	$16.9M-1.0%	$17.1M	N/A
SG&A Expenses	$5.7M-0.1%	$5.7M+0.7%	$5.7M	N/A	$6.2M+5.3%	$5.9M+11.8%	$5.3M	N/A
Operating Income	-$27.9M+2.5%	-$28.6M+1.5%	-$29.0M	N/A	-$23.2M-2.1%	-$22.8M-2.0%	-$22.3M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$26K-45.8%	$48K+166.7%	$18K	N/A	$43K	N/A	$46K	N/A
Net Income	-$26.1M+3.3%	-$27.0M+1.7%	-$27.5M	N/A	-$21.0M-3.5%	-$20.3M-3.2%	-$19.7M	N/A
EPS (Diluted)	$-0.40+14.9%	$-0.47+14.5%	$-0.55	N/A	$-0.42-2.4%	$-0.41-2.5%	$-0.40	N/A

AURA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$169.4M-7.2%	$182.5M-28.5%	$255.1M+13.9%	$223.9M+39.9%	$160.0M+624.0%	$22.1M
Current Assets	$149.7M-6.8%	$160.6M-30.7%	$231.8M+17.8%	$196.7M+28.0%	$153.7M+732.9%	$18.5M
Cash & Equivalents	$59.5M+87.8%	$31.7M-22.8%	$41.1M-66.2%	$121.6M-18.4%	$149.1M+757.0%	$17.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$32.5M+6.5%	$30.5M+4.5%	$29.2M+3.1%	$28.4M+267.5%	$7.7M-94.1%	$130.8M
Current Liabilities	$18.4M+23.3%	$14.9M+20.7%	$12.4M+18.2%	$10.5M+42.2%	$7.4M+176.4%	$2.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$136.9M-9.9%	$152.0M-32.7%	$225.8M+15.5%	$195.6M+28.4%	$152.3M+240.1%	-$108.7M
Retained Earnings	-$480.4M-28.4%	-$374.2M-30.3%	-$287.3M-36.2%	-$210.9M-38.6%	-$152.1M-30.2%	-$116.9M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$190.0M-7.0%	$204.4M+31.5%	$155.4M-14.9%	$182.5M-11.1%	$205.3M-5.9%	$218.3M-7.1%	$235.0M-7.9%	$255.1M
Current Assets	$170.1M-7.5%	$184.0M+36.8%	$134.5M-16.3%	$160.6M-12.5%	$183.5M-6.2%	$195.6M-7.8%	$212.2M-8.4%	$231.8M
Cash & Equivalents	$47.6M-55.7%	$107.4M+180.9%	$38.2M+20.6%	$31.7M+24.7%	$25.4M-15.5%	$30.1M+14.4%	$26.3M-36.0%	$41.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$33.4M+12.1%	$29.8M+8.5%	$27.4M-10.1%	$30.5M-0.5%	$30.7M+14.3%	$26.8M+2.2%	$26.2M-10.2%	$29.2M
Current Liabilities	$18.8M+26.7%	$14.9M+22.1%	$12.2M-18.4%	$14.9M+1.4%	$14.7M+39.5%	$10.5M+9.2%	$9.7M-21.8%	$12.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$156.7M-10.3%	$174.6M+36.5%	$128.0M-15.8%	$152.0M-13.0%	$174.7M-8.8%	$191.5M-8.3%	$208.8M-7.6%	$225.8M
Retained Earnings	-$454.9M-6.1%	-$428.7M-6.7%	-$401.7M-7.3%	-$374.2M-7.4%	-$348.4M-6.4%	-$327.4M-6.6%	-$307.0M-6.9%	-$287.3M

AURA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$84.7M-6.2%	-$79.8M-25.0%	-$63.8M-16.9%	-$54.6M-68.5%	-$32.4M-33.3%	-$24.3M
Capital Expenditures	$447K-64.3%	$1.3M+76.7%	$709K-35.2%	$1.1M-48.5%	$2.1M+175.6%	$771K
Free Cash Flow	-$85.2M-5.1%	-$81.1M-25.6%	-$64.6M-15.9%	-$55.7M-61.3%	-$34.5M-37.6%	-$25.1M
Investing Cash Flow	$35.6M-48.3%	$68.8M+160.4%	-$114.0M-67.9%	-$67.9M-3093.8%	-$2.1M-175.6%	-$771K
Financing Cash Flow	$77.2M+4737.3%	$1.6M-98.4%	$97.3M+1.7%	$95.6M-42.5%	$166.3M+1556.6%	$10.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$20.1M+3.0%	-$20.8M+11.1%	-$23.4M+2.5%	-$24.0M-56.8%	-$15.3M+5.3%	-$16.1M+34.0%	-$24.5M-40.6%	-$17.4M
Capital Expenditures	$45K+15.4%	$39K-79.1%	$187K-37.5%	$299K-12.3%	$341K-35.0%	$525K+496.6%	$88K-72.2%	$317K
Free Cash Flow	-$20.2M+3.0%	-$20.8M+11.6%	-$23.5M+2.9%	-$24.3M-55.3%	-$15.6M+6.2%	-$16.7M+32.1%	-$24.5M-38.6%	-$17.7M
Investing Cash Flow	-$44.0M-320.3%	$20.0M-33.0%	$29.8M+0.4%	$29.7M+200.3%	$9.9M-50.2%	$19.8M+111.2%	$9.4M+110.4%	-$90.1M
Financing Cash Flow	$4.4M-93.8%	$69.9M+72742.7%	$96K-82.3%	$543K-24.2%	$716K+762.7%	$83K-67.2%	$253K-99.7%	$93.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AURA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-77.6%-20.4pp	-57.2%-23.4pp	-33.8%-3.8pp	-30.0%-6.9pp	-23.1%	N/A
Return on Assets	-62.7%-15.1pp	-47.6%-17.7pp	-30.0%-3.7pp	-26.2%-4.2pp	-22.0%+78.4pp	-100.5%
Current Ratio	8.15-2.6	10.77-8.0	18.76-0.1	18.81-2.1	20.90+14.0	6.94
Debt-to-Equity	0.24+0.0	0.20+0.1	0.13-0.0	0.14+0.1	0.05+1.3	-1.20
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-16.7%-1.2pp	-15.5%+6.0pp	-21.5%	N/A	-12.0%-1.4pp	-10.6%-1.2pp	-9.4%	N/A
Return on Assets	-13.8%-0.5pp	-13.2%+4.5pp	-17.7%	N/A	-10.3%-0.9pp	-9.3%-0.9pp	-8.4%	N/A
Current Ratio	9.04-3.3	12.39+1.3	11.06+0.3	10.77-1.7	12.47-6.1	18.54-3.4	21.97+3.2	18.76
Debt-to-Equity	0.21+0.0	0.17-0.0	0.21+0.0	0.20+0.0	0.18+0.0	0.14+0.0	0.130.0	0.13
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Lexicon Pharmaceuticals Inc LXRX

$639.8M

Solid Bioscience SLDB

$638.6M

AUTOLUS THERAPEUTICS PLC AUTL

$338.0M

Adc Therapeutics Sa ADCT

$462.4M

Replimune Group REPL

$594.5M

Frequently Asked Questions

Is Aura Biosciences, Inc. profitable?

No, Aura Biosciences, Inc. (AURA) reported a net income of -$106.2M in fiscal year 2025.

What is Aura Biosciences, Inc.'s EBITDA?

Aura Biosciences, Inc. (AURA) had EBITDA of -$111.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Aura Biosciences, Inc.'s return on equity (ROE)?

Aura Biosciences, Inc. (AURA) has a return on equity of -77.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Aura Biosciences, Inc.'s free cash flow?

Aura Biosciences, Inc. (AURA) generated -$85.2M in free cash flow during fiscal year 2025. This represents a -5.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Aura Biosciences, Inc.'s operating cash flow?

Aura Biosciences, Inc. (AURA) generated -$84.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Aura Biosciences, Inc.'s total assets?

Aura Biosciences, Inc. (AURA) had $169.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Aura Biosciences, Inc.'s capital expenditures?

Aura Biosciences, Inc. (AURA) invested $447K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Aura Biosciences, Inc. spend on research and development?

Aura Biosciences, Inc. (AURA) invested $90.3M in research and development during fiscal year 2025.

How many shares does Aura Biosciences, Inc. have outstanding?

Aura Biosciences, Inc. (AURA) had 64M shares outstanding as of fiscal year 2025.

What is Aura Biosciences, Inc.'s current ratio?

Aura Biosciences, Inc. (AURA) had a current ratio of 8.15 as of fiscal year 2025, which is generally considered healthy.

What is Aura Biosciences, Inc.'s debt-to-equity ratio?

Aura Biosciences, Inc. (AURA) had a debt-to-equity ratio of 0.24 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Aura Biosciences, Inc.'s return on assets (ROA)?

Aura Biosciences, Inc. (AURA) had a return on assets of -62.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Aura Biosciences, Inc.'s cash runway?

Based on fiscal year 2025 data, Aura Biosciences, Inc. (AURA) had $59.5M in cash against an annual operating cash burn of $84.7M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Aura Biosciences, Inc.'s Piotroski F-Score?

Aura Biosciences, Inc. (AURA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Aura Biosciences, Inc.'s earnings high quality?

Aura Biosciences, Inc. (AURA) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.